JOHNSON & JOHNSON
JNJ evidence brief
What we can confirm
- BioSniper Score:
- 7.0 / 10
- Market Cap:
- $647.83B
- Lead Asset:
- 2.5 mhz phased array sector meridian probe
What it means
What to watch
Prepared research question
What matters most for JNJ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · JNJ
Johnson & Johnson (JNJ) is a diversified healthcare conglomerate with a strong pharmaceutical pipeline in oncology and immunology, supported by a large medical technology portfolio and recent regulatory and clinical milestones.
Key risk: Patent cliff 2026
BioSniper Score
Based on 4 of 6 signals
Market Cap
$647.83B
Cash Runway
—
Lead Asset
2.5 mhz phased array sector meridian probe
Next Catalyst
—
Financial data as of Jun 28, 2026.
Tracking 307 pipeline candidates · 34 clinical trials for JOHNSON & JOHNSON.
Johnson & Johnson (JNJ) is a diversified healthcare conglomerate with a strong pharmaceutical pipeline in oncology and immunology, supported by a large medical technology portfolio and recent regulatory and clinical milestones.
- Cash & equivalents of $20,422.0M as of 2026-06-28 [sec]
- Total revenue of $25,310.0M and net income of $5,534.0M as of 2026-06-28 [sec]
- Shareholders' equity of $84,971.0M and total debt of $49,036.0M as of 2026-06-28 [sec]
- Positive regulatory developments in Europe for multiple myeloma therapy Tecvayli used in combination with Darzalex SC [news · 2026-07-01]
- Breakthrough Phase 2/3 ENERGY trial results for IMAAVY (nipocalimab) in warm autoimmune hemolytic anemia, with FDA Priority Review [news · 2026-06-14]
What works
- Strong pharmaceutical pipeline with positive late-stage data and regulatory milestones across multiple therapies, including TECVAYLI, amivantamab-based regimens, and TREMFYA [news · 2026-06-09]
- Expanding oncology pipeline through acquisition of Firefly Bio and progress on JNJ-1900 (NBTXR3) for inoperable non-small cell lung cancer [news · 2026-07-01][news · 2026-05-18]
- Company sees path to double-digit growth above its previously stated 5% to 7% long-term range, supported by pharma pipeline, med tech portfolio, and capital flexibility [news · 2026-09-17]
What to weigh
- Collapsing blockbuster drug and mounting litigation costs threaten to cancel out gains [news · 2026-09-28]
- Stelara faces biosimilar pressure, requiring focus on Tremfya and newly approved Icotyde to maintain immunology growth [news · 2026-05-12]
- Patent cliff in 2026 poses a challenge to growth [news · 2026-09-17]
From the filings
Quoted directly from source documents.
Positive regulatory developments in Europe for multiple myeloma therapy Tecvayli
“Johnson & Johnson (NYSE:JNJ) received positive regulatory developments in Europe for multiple myeloma therapy Tecvayli used in combination with Darzalex SC, supported by phase III trial data.”
News · July 1, 2026
Breakthrough Phase 2/3 ENERGY trial results for IMAAVY (nipocalimab) in warm autoimmune hemolytic anemia
“Johnson & Johnson (NYSE:JNJ) reported breakthrough Phase 2/3 ENERGY trial results for IMAAVY (nipocalimab) in warm autoimmune hemolytic anemia, a rare anemia with no current FDA approved therapies.”
News · June 14, 2026
Company sees path to double-digit growth above 5-7% range
“Johnson & Johnson (NYSE:JNJ) Executive Vice President and Chief Financial Officer Joe Wolk said the company sees a path to growth above its previously stated 5% to 7% long-term range, supported by its pharmaceutical pipeline, medical technology portfolio and capital flexibility.”
News · September 17, 2026
Collapsing blockbuster drug and mounting litigation costs threaten gains
“Johnson & Johnson's oncology and immunology pipeline is firing on multiple cylinders, but a collapsing blockbuster drug and mounting litigation costs threaten to cancel out every gain.”
News · September 28, 2026
Catalyst timeline
- 2023-09-07 · Phase3_Start: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Multidose Clinical Trial to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy — Initiation of a Phase 3 trial for a fixed combination analgesic in postoperative pain.
- 2025-01-30 · Phase2_Start: A Phase II Study of Itacitinib in Patients With Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors — Start of a Phase 2 study for itacitinib in immune-related adverse events.
- 2026-06-03 · Phase3_Start: Bumetanide vs. Furosemide for Adults Hospitalized With Cirrhosis: the BUFF Trial — Initiation of a Phase 3 trial comparing bumetanide and furosemide in hospitalized cirrhosis patients.
Risks & what to watch (3)›
Key risks
- Patent cliff 2026 — Patent cliff in 2026 poses a challenge to growth [news · 2026-09-17]
- Litigation costs — Mounting litigation costs threaten to cancel out gains [news · 2026-09-28]
- Biosimilar pressure on Stelara — Stelara faces biosimilar pressure, requiring focus on Tremfya and Icotyde [news · 2026-05-12]
What to watch
- Progress of JNJ-1900 (NBTXR3) Phase 2 trial in inoperable non-small cell lung cancer [news · 2026-05-18]
- FDA Priority Review decision for IMAAVY (nipocalimab) in warm autoimmune hemolytic anemia [news · 2026-06-14]
- Impact of Stelara biosimilar competition on immunology franchise revenue [news · 2026-05-12]
- Outcome of talc litigation cases and their effect on financials [news · 2026-07-01]
Sources: Catalysts · News · Generated October 13, 2026 · How we verify sources →
Run JOHNSON & JOHNSON through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available JOHNSON & JOHNSON facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.37 · 1% dilution
Lead: Approved
307 candidates
No upcoming catalysts tracked
0 buys · 9 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 1.0%
- Days to cover
- 2.9
- Shares short
- 22,349,005
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
JNJ short interestGovernance
Frequently asked questions
What is the AI investment thesis for JOHNSON & JOHNSON?
Johnson & Johnson (JNJ) is a diversified healthcare conglomerate with a strong pharmaceutical pipeline in oncology and immunology, supported by a large medical technology portfolio and recent regulatory and clinical milestones.
Who is the CEO of JOHNSON & JOHNSON?
Mr. Joaquin Duato is the chief executive officer of JOHNSON & JOHNSON (JNJ).
Where is JOHNSON & JOHNSON headquartered?
JOHNSON & JOHNSON (JNJ) is headquartered in New Brunswick, NJ, United States.
What therapeutic areas does JOHNSON & JOHNSON focus on?
JOHNSON & JOHNSON develops therapies across Oncology, Neurology, Immunology, Ophthalmology, Respiratory, Pain, Dermatology, Gastroenterology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.